{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '6.1.6.', 'Part 3 Secondary Objectives', '34', '7.', 'OVERALL STUDY DESIGN AND PLAN', '34', '7.1.', 'Endpoints', '37', '7.1.1.', 'Part 1 Primary Efficacy Endpoint', '37', '7.1.2.', 'Part 1 Secondary Efficacy Endpoints', '37', '7.1.3.', 'Part 1 Exploratory Efficacy Endpoints', '37', '7.1.4.', 'Part 1 Safety Endpoints', '38', '7.1.5.', 'Part 1 Health Outcome Endpoints', '38', '7.1.6.', 'Part 2 Primary Endpoints', '38', '7.1.7.', 'Part 2 Secondary Endpoints', '38', '7.1.8.', 'Part 3 Primary Endpoints', '39', '7.1.9.', 'Part 3 Secondary Endpoints', '39', '8.', 'SELECTION AND WITHDRAWAL OF SUBJECTS', '39', '8.1.', 'Number of Subjects', '39', '8.2.', 'Subject Selection', '39', '8.2.1.', 'Inclusion Criteria', '39', '8.2.2.', 'Exclusion Criteria', '42', '8.3.', 'Subject Withdrawal from the Study and from Study Drug', '44', '8.3.1.', 'Subject Withdrawal from the Study', '44', '8.3.2.', 'Subject Discontinuation from Study Drug', '45', '8.4.', 'End of Study Definition', '46', '9.', 'TREATMENT OF SUBJECTS', '46', '9.1.', 'Description of Study Drug and Study Drug Product', '46', '9.2.', 'Description of Study Drug Packaging, Labeling, and Storage', '46', '9.3.', 'Randomization and Study Drug Blinding', '47', '9.3.1.', 'Blinding', '47', '9.3.2.', 'Randomization', '47', '9.3.2.1.', 'Part 1 Randomization', '47', '9.3.2.2.', 'Part 2 Randomization', '48', '9.4.', 'Study Drug Administration and Treatment Compliance', '49', '9.5.', 'Study Drug Dose Modification', '50', '9.6.', 'Study Drug (Investigational Medicinal Product) Accountability', '50', '9.7.', 'Concomitant Medications', '51', '17']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 4.0', 'CONFIDENTIAL', 'BCX7353-302', '9.7.1.', 'Prohibited Medications', '51', '10.', 'STUDY CONDUCT', '52', '10.1.', 'Overview', '52', '10.2.', 'Schedule of Assessments', '53', '10.3.', 'Study Visits', '62', '10.3.1.', 'Screening Visit', '62', '10.3.2.', 'Period Between Screening and Baseline', '63', '10.3.3.', 'Part 1', '65', '10.3.3.1.', 'Baseline Visit (Day 1)', '65', '10.3.3.2.', 'Week 2 Visit', '66', '10.3.3.3.', 'Week 4, 8, 12, and 18 Visits', '66', '10.3.3.4.', 'Week 24 Visit', '67', '10.3.4.', 'Part 2', '68', '10.3.4.1.', 'Week 26 Visit', '68', '10.3.4.2.', 'Week 28, 32, 36, and 48 Visits', '68', '10.3.4.3.', 'Week 40 and 44 Phone calls', '69', '10.3.5.', 'Part 3', '69', '10.3.5.1.', 'Week 60, 72, 84, and 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216,', '228, and 240 Visits', '69', '10.3.5.2.', 'Week 52, 56, 64, 68, 76, 80, 88, and 92 Phone Calls', '70', '10.3.6.', 'Follow-up/Early Termination Visit', '70', '11.', 'ASSESSMENTS', '71', '11.1.', 'Chronology of Assessments', '71', '11.2.', 'Investigator-Completed Assessments', '71', '11.2.1.', 'HAE Medical and Medication History', '71', '11.2.2.', 'Physical Examination', '71', '11.2.3.', 'Weight/Body Mass Index', '72', '11.2.4.', '12-lead Electrocardiograms', '72', '11.2.5.', 'Vital Signs', '72', '11.2.6.', 'Clinical Laboratory Evaluations', '72', '11.2.7.', 'Screening for Human Immunodeficiency Virus, Hepatitis B, and Hepatitis C', 'Serology', '75', '11.2.8.', 'HLA Typing', '75', '18']\n\n###\n\n", "completion": "END"}